Mildronate (Meldonium Dihydrate)

Meldonium Dihydrate blocks the enzyme gamma‑butyrobetaine hydroxylase, which lowers the synthesis of carnitine. This reduces fatty‑acid oxidation in heart cells and shifts energy production toward glucose oxidation, a pathway that uses less oxygen per unit of ATP. The metabolic shift enhances cardiac efficiency during periods of limited oxygen supply.

The dosage of Mildronate is individualized and determined by the prescribing physician based on the patient’s clinical condition, severity of disease, and response to therapy. Healthcare professionals consider factors such as weight, renal function, and concomitant medications when establishing the appropriate regimen.

Safety data for Mildronate during pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should be used only if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare provider.

To order Mildronate, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams across international markets. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain if required) and any necessary import documentation.

The primary alternative to Mildronate in the metabolic‑modulator class is trimetazidine, which also shifts myocardial energy use toward glucose. While both aim to improve cardiac efficiency, Meldonium reduces carnitine synthesis, whereas trimetazidine inhibits fatty‑acid β‑oxidation directly. Clinical choice depends on patient tolerance, specific cardiac profile, and physician preference.

Mildronate injectable solution must be stored at 2‑8 °C (refrigerated). Keep the product in its original container, protect it from light, and avoid freezing or vigorous shaking. If the solution reaches room temperature for a short period, it may be used, but it should be returned to the refrigerator promptly.

Mildronate is administered intravenously by a qualified healthcare professional. The solution is typically infused over a short period, as directed by the prescribing physician. Administration should follow aseptic technique, and the infusion rate may be adjusted based on patient tolerance and clinical response.

The most serious risks include severe hypotension, life‑threatening arrhythmias, anaphylactic or severe allergic reactions, hepatic dysfunction, and rare cases of cardiogenic shock. Patients should be monitored for sudden drops in blood pressure, irregular heart rhythms, signs of allergic response, and abnormal liver function tests during therapy.

Mildronate is contraindicated in patients with known hypersensitivity to meldonium or any excipients in the formulation. It should also be avoided in individuals with severe uncontrolled hypotension, active severe cardiac arrhythmias, or those receiving conflicting metabolic modulators without medical supervision.